These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8429674)

  • 61. Expression and modulation of annexin VIII in human leukemia-lymphoma cell lines.
    Hu ZB; Ma W; Uphoff CC; Drexler HG
    Leuk Res; 1993 Nov; 17(11):949-57. PubMed ID: 8231235
    [TBL] [Abstract][Full Text] [Related]  

  • 62. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
    Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
    Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
    [TBL] [Abstract][Full Text] [Related]  

  • 63. In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Boise L; Westin E; Howe C; Pettit GR; Turner A; McCrady C
    Biochem Pharmacol; 1991 Jul; 42(4):853-67. PubMed ID: 1867641
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S; Jarvis WD; Swerdlow PS; Turner AJ; Traylor RS; Wallace HJ; Lin PS; Pettit GR; Gewirtz DA
    Cancer Res; 1992 Nov; 52(22):6270-8. PubMed ID: 1423273
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells.
    Dell'Aquila ML; Nguyen HT; Herald CL; Pettit GR; Blumberg PM
    Cancer Res; 1987 Nov; 47(22):6006-9. PubMed ID: 3478136
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line.
    Liu KZ; Schultz CP; Johnston JB; Beck FW; Al-Katib AM; Mohammad RM; Mantsch HH
    Leukemia; 1999 Aug; 13(8):1273-80. PubMed ID: 10450757
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells.
    Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG
    Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
    Grant S; Pettit GR; Howe C; McCrady C
    Leukemia; 1991 May; 5(5):392-8. PubMed ID: 2033960
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
    Hornung RL; Pearson JW; Beckwith M; Longo DL
    Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Phorbol ester and bryostatin effects on growth and the expression of oestrogen responsive and TGF-beta 1 genes in breast tumour cells.
    Nutt JE; Harris AL; Lunec J
    Br J Cancer; 1991 Oct; 64(4):671-6. PubMed ID: 1911215
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
    Chelliah J; Freemerman AJ; Wu-Pong S; Jarvis WD; Grant S
    Biochem Pharmacol; 1997 Sep; 54(5):563-73. PubMed ID: 9337072
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines.
    Nabha SM; Wall NR; Mohammad RM; Pettit GR; Al-Katib AM
    Anticancer Drugs; 2000 Jun; 11(5):385-92. PubMed ID: 10912955
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
    McCrady CW; Li F; Pettit GR; Grant S
    Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
    Kitada S; Zapata JM; Andreeff M; Reed JC
    Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
    Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
    Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Isoenzyme studies in human leukemia-lymphoma cells lines--II. Acid phosphatase.
    Drexler HG; Gaedicke G; Minowada J
    Leuk Res; 1985; 9(5):537-48. PubMed ID: 3874327
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Successful treatment of murine melanoma with bryostatin 1.
    Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
    Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase calpha.
    Gschwend JE; Fair WR; Powell CT
    Mol Pharmacol; 2000 Jun; 57(6):1224-34. PubMed ID: 10825394
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
    Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
    Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.